Damon R. Reed, MD, compared the carefully-considered off-label use of trastuzumab deruxtecan with a clinical trial experience in 2 rare sarcoma subtypes.
Damon R. Reed, MD
Advertisement
Damon R. Reed, MD, is head of the Solid Tumor Oncology Division in Pediatrics at Memorial Sloan Kettering Cancer Center.
Articles by Damon R. Reed, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Most Patients Prefer SC Over IV Pembrolizumab, Phase 2 Data Show
2
Gedatolisib Combinations Nearly Double PFS in PIK3CA-Mutant Breast Cancer
3
First Patients Dosed With DOC1021 in Phase 1/2 Melanoma Trial
4
Tucatinib Maintenance Extends PFS Across HER2+ Breast Cancer Subgroups
5